High-purity CJC-1295 No DAC and Ipamorelin research compounds represent critical reagents for evaluating secretagogue synergy within the mammalian somatotropic axis. PX1 Research provides USA-manufactured, analytically validated peptide formulations backed by lot-specific mass spectrometry and HPLC purity reports for quantitative in vitro and preclinical research applications.
High-purity CJC-1295 No DAC and Ipamorelin research compounds represent critical reagents for evaluating secretagogue synergy within the mammalian somatotropic axis. PX1 Research provides USA-manufactured, analytically validated peptide formulations backed by lot-specific mass spectrometry and HPLC purity reports for quantitative in vitro and preclinical research applications.
When sourcing CJC-1295 No DAC and Ipamorelin for laboratory research, investigators require high-purity, fully characterized synthetic peptides free of trifluoroacetic acid (TFA) residual salts and bacterial endotoxins. This dual-secretagogue formulation combines a short-acting GHRH analog with a selective ghrelin receptor agonist to study pulsatile growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) signaling in preclinical tissue repair models.
Researchers evaluating cjc 1295 ipamorelin no dac for sale must prioritize analytical validation over commercial claims. Laboratory-grade preparations manufactured under strict quality standards ensure reproducibility across cell culture assays and animal models. PX1 Research provides fully documented compounds accompanied by third-party testing metrics to satisfy stringent experimental protocols.
CJC-1295 No DAC, structurally identified as Modified GRF 1-29 (Mod GRF 1-29), is a 29-amino-acid synthetic peptide derived from the active N-terminal domain of endogenous Growth Hormone-Releasing Hormone (GHRH). The native GHRH peptide (1-44) is rapidly degraded in vivo by dipeptidyl peptidase-IV (DPP-IV). To enhance enzymatic resistance while maintaining receptor affinity, Mod GRF 1-29 incorporates four amino acid substitutions: Tyr1 to D-Ala2, Gln8 to Asp8, Gly15 to Ala15, and Leu27 to Lys27.
Unlike CJC-1295 with DAC (Drug Affinity Complex), which incorporates a maleimidopropionic acid linker to bind plasma albumin and extend terminal half-life to several days, CJC-1295 No DAC retains a short physiological half-life of approximately 30 minutes in animal models. This rapid clearance allows investigators to mimic natural, pulsatile GHRH signaling without inducing persistent receptor saturation or altering basal endocrine rhythms.
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It functions as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), commonly referred to as the ghrelin receptor. Binding of Ipamorelin to GHS-R1a initiates an intracellular signaling cascade mediated by phospholipase C (PLC) and inositol trisphosphate (IP3), triggering the release of stored intracellular calcium within pituitary somatotropes.
A distinguishing biochemical feature of Ipamorelin in preclinical literature is its high selectivity for growth hormone release. Unlike earlier growth hormone-releasing peptides (GHRPs), in vitro pituitary cell assays demonstrate that Ipamorelin does not induce significant transcription or secretion of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, even at supramaximal concentrations. This selectivity makes it a clean molecular probe for isolating somatotropic signaling.
The combination of CJC-1295 No DAC and Ipamorelin targets two distinct receptor pathways on anterior pituitary somatotropes. GHRH analogs activate the GHRH receptor, triggering Gs protein coupling, adenylyl cyclase activation, and an increase in intracellular cyclic adenosine monophosphate (cAMP). Conversely, GHS-R1a agonists operate through Gq protein coupling, elevating intracellular calcium ions via the IP3 pathway.
Preclinical studies demonstrate that simultaneous activation of the cAMP-protein kinase A pathway and the IP3-calcium pathway results in a synergistic, rather than additive, release of growth hormone. Co-administration in animal models yields a robust, naturalistic pulse of endogenous GH, which subsequently stimulates hepatic transcription of insulin-like growth factor 1 (IGF-1). This physiological surge supports research into downstream cellular repair mechanisms without desensitizing pituitary receptors.
Studied primarily as a long-acting growth-hormone-releasing hormone analog framework, CJC-1295 No DAC combined with Ipamorelin serves as a foundational model for investigating tissue regeneration and metabolic regulation. Endogenous GH and IGF-1 play critical roles in activating satellite cells during skeletal muscle repair, enhancing collagen synthesis in extracellular matrix structures, and promoting osteoblast activity in bone remodeling assays.
In vitro data indicate that secretagogue-driven IGF-1 signaling accelerates microvascular endothelial cell migration and fibroblast proliferation. In rodent models of musculoskeletal injury, dual-secretagogue protocols have been used to evaluate nitrogen retention, cellular protein synthesis, and lipid oxidation rates. Exploring these pathways provides key insights into counteracting catabolic states and cell senescence in isolated models.
To select the appropriate reagent for specific research models, investigators must differentiate between various peptides operating within the growth hormone axis. The table below highlights key parameters across related compounds available in our PX1 Research catalog:
While CJC-1295 DAC provides continuous GHRH receptor stimulation useful for studying baseline endocrine suppression, CJC-1295 No DAC allows precise control over secretagogue exposure timing. When combined with Ipamorelin, it provides a highly controlled alternative to non-selective agents like GHRP-2 or potent GHRH analogs such as Tesamorelin.
Validating analytical purity is paramount when conducting quantitative biochemical research. Synthetic peptides synthesized via solid-phase peptide synthesis (SPPS) can retain trace impurities, including deletion sequences, truncated peptides, and counter-ion residues like TFA. High-performance liquid chromatography (RP-HPLC) with UV detection at 214 nm is utilized to establish chromatographic purity, requiring a threshold of ≥99.0%.
Mass spectrometry (LC-MS) confirms exact molecular weight, verifying peptide sequence identity against theoretical values. Furthermore, for cell culture and preclinical assays, bacterial endotoxin content must be measured using Limulus Amebocyte Lysate (LAL) testing. PX1 Research ensures that every batch undergoes ISO 17025 accredited laboratory verification, maintaining endotoxin levels strict below 0.5 EU/mg to prevent confounding inflammatory responses in research protocols.
Proper handling procedures are essential to preserve the structural integrity of lyophilized peptide cakes and reconstituted stock solutions. Lyophilized CJC-1295 No DAC and Ipamorelin vials should be stored at -20°C or -80°C for long-term preservation, protected from light and moisture exposure.
Reconstitution should be performed using sterile, laboratory-grade bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline under a laminar flow hood. Gently direct the diluent down the glass vial wall rather than directly onto the lyophilized powder, allowing the compound to dissolve naturally without vigorous vortexing. Reconstituted solutions should be aliquoted into single-use polypropylene tubes to minimize freeze-thaw degradation and stored at 2°C to 8°C for short-term evaluation.
Selecting a reliable supplier for synthetic research reagents requires strict adherence to quality verification, transparency, and domestic logistics. PX1 Research synthesizes all compounds in domestic, GMP-compliant facilities within the USA. Each lot undergoes comprehensive third-party testing, with downloadable Certificates of Analysis (COAs) documenting purity, mass identity, and endotoxin levels.
Whether preparing small-scale cell assays or expanding preclinical animal cohorts, laboratories can secure standardized reagents through our wholesale research accounts. Orders dispatch same-day from our strategically positioned distribution hubs in California and Arizona, ensuring prompt delivery and minimal thermal exposure during transit. Explore our complete selection of research peptides to support your institution's ongoing investigations.
What is the difference between CJC-1295 No DAC and CJC-1295 With DAC?
CJC-1295 No DAC (Mod GRF 1-29) lacks the Drug Affinity Complex (DAC) modification. It exhibits a short half-life (~30 minutes), creating discrete pulses of growth hormone release. CJC-1295 With DAC binds to serum albumin, extending its biological half-life to several days and producing continuous elevation of GH levels.
Why combine CJC-1295 No DAC with Ipamorelin in research models?
Combining a GHRH analog (CJC-1295 No DAC) with a GHS-R1a agonist (Ipamorelin) produces a synergistic release of growth hormone in preclinical models. This dual activation engages both the cAMP and intracellular calcium pathways in pituitary somatotropes, yielding a physiological GH pulse superior to either compound administered alone.
What analytical purity standards does PX1 Research guarantee?
PX1 Research guarantees a minimum of 99.0% chemical purity for research peptides, verified via Reverse-Phase HPLC and Liquid Chromatography-Mass Spectrometry (LC-MS). Every lot is accompanied by a third-party COA from an ISO 17025 accredited laboratory.
What are the endotoxin limits for PX1 Research compounds?
All peptide lots undergo quantitative Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain strictly below 0.5 EU/mg, ensuring suitability for sensitive cell culture and in vivo animal models.
How should CJC-1295 No DAC and Ipamorelin be reconstituted for lab use?
Vials should be reconstituted using sterile bacteriostatic water or sterile 0.9% saline. The solvent should be introduced gently along the internal glass wall. Avoid aggressive agitation or vortexing to prevent peptide denaturing.
Does Ipamorelin affect cortisol or prolactin levels in preclinical assays?
In vitro and animal studies demonstrate that Ipamorelin is highly selective for the GHS-R1a receptor and does not significantly induce the release of ACTH, cortisol, or prolactin, unlike older GHRP compounds like GHRP-2 or GHRP-6.
How should reconstituted peptide solutions be stored?
Reconstituted liquid stock solutions should be stored at 2°C to 8°C for short-term experimental protocols (up to 30 days) or aliquoted into single-use tubes and stored at -20°C or -80°C to prevent degradation from repeated freeze-thaw cycles.
Where are PX1 Research peptides manufactured and shipped from?
PX1 Research peptides are synthesized in USA-based, GMP-compliant facilities. Orders are fulfilled and shipped same-day (Monday–Friday) from primary logistics centers located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.